Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
Taking advantage of the immune system to exert an antitumor effect is currently a novel approach in cancer therapy. Adoptive transfer of T cells engineered to express chimeric antigen receptors (CARs) targeting a desired antigen has shown extraordinary antitumor activity, especially in refractory an...
Main Authors: | Jiali Cheng, Lei Zhao, Yuanyuan Zhang, Yun Qin, Yuqi Guan, Tong Zhang, Chaohong Liu, Jianfeng Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.01237/full |
Similar Items
-
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
by: Kristen B. Long, et al.
Published: (2018-12-01) -
Innovative CAT-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
by: Yuna Jo, et al.
Published: (2020-07-01) -
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
by: Laura Castelletti, et al.
Published: (2021-02-01) -
Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies
by: Joslyn L. Mangal, et al.
Published: (2021-03-01) -
CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
by: Tongjuan Li, et al.
Published: (2020-08-01)